WOBURN, Mass., Sept. 15, 2022 /PRNewswire/ -- Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the Brazilian National Agency of Supplementary Health (ANS) approved SIR-Spheres® Y-90 resin microspheres for the treatment of intermediate and advanced stage hepatocellular carcinoma (HCC) in Brazil.
Sirtex Medical, maker of a radioactive microsphere implant for treating liver tumors, has made a strategic investment in the developer of a prostate cancer therapy featuring laser-charged gold particles, Nanospectra Biosciences.
Sirtex Medical, a leading manufacturer of targeted liver cancer therapies in the U.S., Australia, Europe and Asia, announced a lead and strategic investment in Nanospectra Biosciences, Inc. (Nanospectra), a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, as part of Nanospectra's Series B-1 round of financing.